Results 21 to 30 of about 137,826 (378)

Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.

PLoS ONE, 2023
ObjectivePoly(ADP-ribose) polymerase (PARP) inhibitors are used for targeted therapy for ovarian cancer with homologous recombination deficiency (HRD). In this study, we aimed to develop a homologous recombination deficiency prediction model to predict ...
Jun Kang, Kiyong Na, Haeyoun Kang, Uiju Cho, Sun Young Kwon, Sohyun Hwang, Ahwon Lee   +6 more
doaj   +2 more sources

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

JCO Precision Oncology, 2023
PURPOSE Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to assess the potential for PARPi in
S. Yndestad, C. Engebrethsen, A. Herencia-Ropero, O. Nikolaienko, Olav K Vintermyr, Reidun Lillestøl, Laura Minsaas, B. Leirvaag, G. Iversen, Bjørnar Gilje, E. Blix, H. Espelid, S. Lundgren, J. Geisler, H. Aase, T. Aas, E. Gudlaugsson, A. Llop-Guevara, V. Serra, E. Janssen, P. Lønning, S. Knappskog, H. P. Eikesdal   +22 more
semanticscholar   +6 more sources

Homologous Recombination Deficiency: Concepts, Definitions, and Assays [PDF]

The Oncologist, 2022
Background Homologous recombination deficiency (HRD) is a phenotype that is characterized by the inability of a cell to effectively repair DNA double-strand breaks using the homologous recombination repair (HRR) pathway.
M. Stewart, Diana Merino Vega, R. Arend, J. Baden, O. Barbash, N. Beaubier, Grace Collins, T. French, Negar M. Ghahramani, Patsy Hinson, P. Jelinic, M. Marton, K. McGregor, Jerod Parsons, L. Ramamurthy, M. Sausen, E. Sokol, A. Stenzinger, Hillary Stires, K. Timms, D. Turco, I. Wang, J. Williams, Elaine Wong-Ho, J. Allen   +24 more
semanticscholar   +3 more sources

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma

Journal of Ovarian Research, 2023
Background Homologous Recombination Deficiency (HRD) is a predictive biomarker for ovarian cancer treated with PARP inhibitors or for breast cancer treated with first-line platinum-based chemotherapy.
Zheng Feng, Di Shao, Yuhang Cai, Rui Bi, Xingzhu Ju, Dongju Chen, Chengcheng Song, Xiaojun Chen, Jin Li, Na An, Yunjin Li, Qing Zhou, Zhihui Xiu, Shida Zhu, Xiaohua Wu, Hao Wen   +15 more
doaj   +2 more sources

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics. [PDF]

Biomark Res
The use of poly(ADP-ribose) polymerase inhibitors (PARPi) revolutionized the treatment of BRCA-mutated cancers. Identifying patients exhibiting homologous recombination deficiency (HRD) has been proved useful to predict PARPi efficacy. However, obtaining
Witz A, Dardare J, Betz M, Michel C, Husson M, Gilson P, Merlin JL, Harlé A.   +7 more
europepmc   +2 more sources

Leveraging homologous recombination deficiency for sarcoma

Die Pathologie
Homologous recombination deficiency (HRD) in tumors correlates with poor prognosis and metastases development. Determining HRD is of major clinical relevance as it can be treated with PARP inhibitors (PARPi). HRD remains poorly investigated in sarcoma, a
L. Planas-Paz, C. Pauli
semanticscholar   +4 more sources

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types [PDF]

JCO Precision Oncology, 2022
PURPOSE Homologous recombination DNA repair deficiency (HRD) is associated with sensitivity to platinum and poly (ADP-ribose) polymerase inhibitors in certain cancer types, including breast, ovarian, pancreatic, and prostate.
MD Shiro Takamatsu, PhD J.B. Brown, MD PhD Ken Yamaguchi, MD PhD Junzo Hamanishi, MD PhD Koji Yamanoi, MD PhD Hisamitsu Takaya, PhD Tomoko Kaneyasu, MD PhD Seiichi Mori, MD PhD Masaki Mandai, MD PhD Noriomi Matsumura   +9 more
semanticscholar   +4 more sources

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer [PDF]

Cancers, 2021
Pancreatic cancer is a treatment-resistant malignancy associated with high mortality. However, defective homologous recombination (HR), a DNA repair mechanism required for high-fidelity repair of double-strand DNA breaks, is a therapeutic vulnerability.
Max M. Wattenberg, Kim A. Reiss
openalex   +4 more sources

Homologous recombination deficiency: cancer predispositions and treatment implications. [PDF]

The Oncologist, 2021
Homologous recombination (HR) is a highly accurate DNA repair mechanism. Several HR genes are established cancer susceptibility genes with clinically actionable pathogenic variants (PVs).
M. Toh, J. Ngeow
semanticscholar   +3 more sources

Genomic Determinants of Homologous Recombination Deficiency across Human Cancers [PDF]

Cancers, 2021
Germline BRCA1/2 mutations associated with HRD are clinical biomarkers for sensitivity to poly-ADP ribose polymerase inhibitors (PARPi) treatment in breast, ovarian, pancreatic, and prostate cancers. However, it remains unclear whether other mutations may also lead to HRD and PARPi sensitivity across a broader range of cancer types.
Tao Qing, Xin‐Feng Wang, Tomi Jun, Li Ding, Lajos Pusztai, Kuan‐lin Huang   +5 more
openalex   +5 more sources